Research Analysts Offer Predictions for PLX FY2026 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Protalix BioTherapeutics in a report issued on Wednesday, September 9th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.29 per share for the year, up from their previous estimate of $0.25. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share.

Protalix BioTherapeutics Trading Up 2.2%

Shares of NYSE PLX opened at $2.73 on Friday. Protalix BioTherapeutics has a one year low of $1.60 and a one year high of $3.19. The firm has a market capitalization of $219.96 million, a PE ratio of -21.00 and a beta of 0.02. The business has a 50-day moving average price of $2.43 and a two-hundred day moving average price of $2.33.

Institutional Trading of Protalix BioTherapeutics

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of Protalix BioTherapeutics during the 2nd quarter valued at about $9,429,000. Dimensional Fund Advisors LP grew its stake in Protalix BioTherapeutics by 932.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock valued at $644,000 after buying an additional 268,099 shares during the last quarter. Two Sigma Securities LLC bought a new position in shares of Protalix BioTherapeutics in the second quarter worth about $41,000. Bank of America Corp DE bought a new stake in Protalix BioTherapeutics during the 2nd quarter valued at approximately $121,000. Finally, Ieq Capital LLC acquired a new stake in Protalix BioTherapeutics in the 2nd quarter valued at approximately $32,000. 16.53% of the stock is currently owned by institutional investors and hedge funds.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.